Clinical Trial Detail

NCT ID NCT04497844
Title A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)
Recruitment Not yet recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Niraparib + Prednisone

Abiraterone + Prednisone

Age Groups: senior adult

No variant requirements are available.